FOLH1 and neoplasm: Prostate-specific membrane antigen (PSMA), a key PCa biomarker [70], was used to functionalize AuNPs with Gd(III) complexes and PSMA ligands, improving both MRI imaging contrast and radiotherapy efficacy through precise tumor targeting and dose minimization (Fig. 3B) [71].